IT leaders prioritizing patient experience, value-based care in 2019, survey finds

FierceHealthcare | March 26, 2019

Ramping up value-based care initiatives and improving the patient experience are top priorities for health IT leaders in 2019, a recent survey found. At the same time, IT executives say they are facing significant technology and operational hurdles to advance these initiatives. Half of the executives surveyed cited the ongoing lack of system interoperability as the biggest challenge. Stoltenberg Consulting’s survey of 300 healthcare executives—a third of survey participants were clinical IT professionals and another third were C-suite leaders—revealed that 42% of executives cited updating technology to improve the patient experience as their top objective in 2019, followed by measuring improvement in patient care (33%).

Spotlight

Imagine a nurse, let’s call her Jill, who faces multiple “scrub-ins” every day as part of her operating room (OR) role. She struggles with a rash on her hands and wrists that just won’t go away, causing both physical and emotional trauma. These recurring and often painful skin conditions – which range from mild irritations to more serious reactions – can persist, despite the care taken by nurses and hospitals. Add to that the toll in sick leaves and absenteeism, and the cost of this condition can be painful to both staff and administration. Despite the care and costs, hospitals have not solved the problem. But there is an answer!


Other News
HEALTHTECH SECURITY

Forescout Acquires CyberMDX to Expand Healthcare Cybersecurity Focus

Forescout Technologies | February 02, 2022

Forescout Technologies, the leader in Active Defense for the Enterprise of Things, today announced its acquisition of CyberMDX, a leading healthcare cybersecurity provider delivering visibility and threat prevention for medical devices and clinical networks. The acquisition further strengthens Forescout’s position as the industry leader in out-of-the-box support for the broadest set of connected device types across IT, IoT, OT and IoMT devices. “Forescout is seeing rapid growth in healthcare, a market the company has always focused attention on from a technology and sales perspective. Cybersecurity for IoMT, much like cybersecurity for OT devices, requires specific expertise and technologies. We are pleased to have the CyberMDX team join Forescout as we continue delivering new capabilities on our market-leading platform and grow our R&D center.” Wael Mohamed, Chief Executive Officer of Forescout Forescout is recognized by many of the world’s largest organizations as the leader in device visibility and control, ensuring customers can see all the devices connected to their networks, continuously and in real-time, and then take automated action to mitigate risks. CyberMDX offers a leading solution for visibility and risk management of IoMT devices. Together, Forescout and CyberMDX have a powerful platform that delivers an easy-to-use, scalable and agentless approach to device visibility, classification, threat detection and incident response focused on IoMT devices to better serve healthcare organizations. “CyberMDX enables hospitals to provide quality care by securing and protecting the systems and devices they rely on every day to treat patients and save lives,” said Amir Magner, President and Co-Founder of CyberMDX. “We are thrilled to join the Forescout team where our innovation can continue to make a profound difference to healthcare organizations around the world.” Broad coverage across all device types is essential as larger organizations, such as healthcare, almost always have a wide variety of device types, including IT and a rapidly expanding number of IoT devices, in addition to IoMT and OT devices. In 2018, Forescout acquired Security Matters, a leading providing of solutions for visibility and risk management for OT systems, which are also known as industrial control systems (ICS). Forescout has the largest number of deployments of OT infrastructure protection solutions globally, with major deployments in critical infrastructure sectors such as energy and utilities. Forrester recently recognized Forescout in its inaugural Industrial Control Systems (ICS) Security Solutions Wave, 2021 as the top vendor for market presence for product revenue, total number of customers and deal size. CyberMDX, which was recognized as a Medical Device Security Solution Leader in The Forrester New Wave™: Connected Medical Device Security, Q2 2020, further demonstrates Forescout’s commitment to providing organizations with the most comprehensive solution across all device types. Recently, Forescout announced that its platform discovered 66% more devices than originally expected at the University Health Network (UHN), a group of four hospitals in Toronto, Canada that includes The Toronto General Hospital, which Newsweek ranked in 2021 as the 4thbest hospital in the world. Among many benefits, UHN is leveraging the Forescout platform to “deal with the exponential increase in the number of IoT devices and ever-increasing volume of sophisticated threats, including ransomware,” according to Kashif Parvaiz, Chief Information Security Officer, at UHN. With the addition of CyberMDX’s solution, Forescout customers will be able to gain deeper visibility and risk management of their IoMT and medical devices. Over the past 20 years, Forescout has built unique strength in device intelligence and network fabric technology for device discovery and classification. The company’s Device Cloud database contains over 15 million device fingerprints and ensures Forescout's customers automatically receive highly specific, out-of-the-box device classification capabilities from the Forescout platform for millions of different types of devices. About Forescout Forescout Technologies, Inc. actively defends the Enterprise of Things by identifying, segmenting and enforcing compliance of every connected thing. Fortune 1000 companies trust Forescout as it provides one of the most widely deployed, enterprise-class platforms at scale across IT, IoT, OT and IoMT managed and unmanaged devices. Forescout arms customers with extensive device intelligence, data and policies to allow organizations across every industry to accurately classify risk, detect anomalies and quickly remediate cyberthreats without disruption of critical business assets. Don’t just see it. Secure it.

Read More

FUTURE OF HEALTHCARE

OmniLife Partners With Redox to Add Patient Referral Management Tool to Its End-to-End Communication Platform for Transplant Hospitals.

OmniLife | March 25, 2022

OmniLife, a health technology communication and collaboration platform, has partnered with Redox, the industry-leading electronic health record integration and healthcare interoperability platform, to create a new integrated patient management tool as part of its overarching platform that provides end-to-end communication solutions for transplant hospitals. The new patient modules, OmniReferral and PatientStatus, will allow transplant centers to easily review new referrals and share updates on patient status to providers and allows transplant centers to customize their own digital forms to make it easier for providers to refer and then monitor the activity and status of transplant patients. The tool also integrates into the EHR patient checklists and allows centers using EHRs to easily share patient status updates with referring providers. OmniReferral and PatientStatus is built to be organ agnostic, allowing centers to use the tool across all organ departments and with any referring provider. OmniLife has been leading efforts to improve communication, decision making, and secure information exchange between all stakeholders in the greater allotransplant ecosystem. Additionally, OmniLife is currently participating in a clinical trial funded by the National Institutes of Health (NIH) for a Small Business Innovation Research (SBIR) which includes notable centers such as UPMC Children’s Hospital of Pittsburgh, Loma Linda University Transplant Institute, and Stanford Health Care Transplant Program. About OmniLife OmniLife is a certified Benefit Corporation focused on maximizing the gift of life for purposes of transplantation and research. OmniLife is the only end-to-end communication and clinical workflow software platform that is built specifically to create a more connected and collaborative allotransplant ecosystem.

Read More

HEALTH TECHNOLOGY

Alcon Strengthens Leadership in IOL Innovation with Launch of Clareon Portfolio in the U.S.

Alcon | March 07, 2022

Alcon the global leader in eye care dedicated to helping people see brilliantly, announced the launch of the Clareon®family of intraocular lenses (IOLs) in the U.S. Utilizing Alcon’s most advanced IOL material, Clareon can deliver consistent visual outcomes and exceptional clarity that lasts.°,1-7The Clareon clarity is born out of a glistening-free§IOL material that has among the lowest levels of haze and subsurface nanoglistenings compared to leading competitor IOLs.†,*,1-3 “We are proud to offer our latest IOL technology in the U.S. and other countries across the globe. At Alcon, we are consistently pushing the boundaries to deliver transformational innovation to cataract surgeons and their patients. Clareon is the result of robust R&D efforts at every level—inventive material science, advanced manufacturing techniques and novel delivery systems—to deliver exceptional, long-lasting clarity.” Ian Bell, President, Global Business & Innovation, Alcon The Clareon portfolio leverages many of the same design characteristics and optics as Alcon’s leading IOLs to help deliver the outcomes surgeons expect.8,9Clareon offers sharp, crisp vision with a proprietary edge designed to help reduce glare and posterior capsular opacification.7The lens’ unique and proven STABLEFORCE®Haptics provide superior axial and rotational stability.*,β,8-14Clareon has been extensively researched, with inclusion in 30 published studies worldwide. Clareon Monofocal and Clareon Toric IOLs have already been implanted in more than one million eyes across more than 70 countries.15 Clareon IOLs are inserted using the next-generation, reusable Clareon Monarch®IVDelivery System, which provides precise and controlled implantation and that was designed specifically for the new Clareon material.15,16Clareon Monofocal is also available in the next-generation automated, single-use delivery system, AutonoMe™. “As one of the investigators for the Clareon pivotal trial, I was immediately impressed with the clarity of the new IOL material, delivery system and the consistent refractive outcomes,” said Dr. Samuel H. Lee, MD, Ophthalmologist, Sacramento, CA.** “Today, the clarity of Clareon persists four years later in my trial patients, with the optic performance that I expect from Alcon IOLs, as well as continued high patient satisfaction.” Clareon Monofocal, Clareon PanOptix®, Clareon PanOptix Toric, Clareon Vivity®and Clareon Vivity Toric IOLs are now available in the U.S. Clareon PanOptix offers patients the possibility of 20/20 vision at distance (far), intermediate (at arm’s length) and near (up close), with continuous vision of 20/25 or better.¥,14,17Clareon Vivity is a non-diffractive extended depth of focus lens with wavefront-shaping X-WAVE™ technology, delivering monofocal-quality distance with excellent intermediate and functional near vision and with a monofocal visual disturbance profile.13,18 Clareon Toric will be available in the U.S. later this year. Alcon will be rolling out the Clareon family of IOLs in international markets throughout 2022 and 2023. There are more than 28 million cataract surgeries performed each year in the world. With the aging population and increased life expectancies, these surgeries are expected to increase 3-4% per year for the next 30 years, leading to an estimated 60 million global cataract surgeries annually by 2045.19 About Cataracts A cataract is a cloudy area in the natural lens of the eye that affects vision. As a cataract develops, the eye's lens gradually becomes hard and cloudy, allowing less light to pass through, which makes it more difficult to see. The vast majority of cataracts result from normal aging, but radiation exposure, taking steroids, diabetes and eye trauma can accelerate their development. Cataracts are the most common age-related eye condition and the leading cause of preventable blindness.20Cataracts are treated by removing the eye's cloudy natural lens and surgically replacing it with an IOL. More than 92% of cataract surgeries are considered successful, and patients typically can return to their normal routines within 24 hours.21 About Clareon IOLs and Delivery Systems The family of Clareon intraocular lenses (IOLs) includes the Clareon Aspheric Hydrophobic Acrylic and Clareon Aspheric Toric IOLs, the Clareon PanOptix Trifocal Hydrophobic IOL, Clareon PanOptix Toric, Clareon Vivity Extended Vision Hydrophobic Posterior Chamber IOL and Clareon Vivity Toric IOLs. Each of these IOLs is indicated for visual correction of aphakia in adult patients following cataract surgery. In addition, the Clareon Toric IOLs are indicated to correct pre-existing corneal astigmatism at the time of cataract surgery. The Clareon PanOptix lens mitigates the effects of presbyopia by providing improved intermediate and near visual acuity while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared to a monofocal IOL. The Clareon Vivity lens mitigates the effects of presbyopia by providing an extended depth of focus. Compared to an aspheric monofocal IOL, the lens provides improved intermediate and near visual acuity while maintaining comparable distance visual acuity. All of these IOLs are intended for placement in the capsular bag. Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting any IOL in a patient with any of the conditions described in the Directions for Use that accompany each IOL. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon, informing them of possible risks and benefits associated with these IOLs. Reference the Directions for Use labelling for each IOL for a complete listing of indications, warnings and precautions. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 24,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care.

Read More

FUTURE OF HEALTHCARE

Rockley Photonics and Medtronic Collaborate to Deliver the Next Generation of Wearable Healthcare Monitoring Devices

Rockley Photonics | March 11, 2022

Rockley Photonics Holdings Limited a global leader in photonics-based health monitoring and communications solutions, announced that it has agreed to enter a development partnership with Medtronic, a global leader in healthcare technology. The two companies plan to collaborate to bring Rockley’s recently announced Bioptx™ biomarker sensing platform into Medtronic’s solutions for use across various healthcare settings. Rockley’s biosensing technology is expected to expand the capabilities of wearable medtech devices by miniaturizing the measurement and analysis of a range of biomarkers into a compact form factor. These advances mean that a single wearable device could monitor multiple crucial biomarkers – including core body temperature, blood pressure, body hydration, alcohol, lactate, and glucose trends, among others. The Bioptx platform offers an end-to-end sensing solution that integrates cloud analytics and artificial intelligence (AI) to potentially deliver a holistic assessment of a variety of conditions. The partnership with Medtronic builds on the societal shift from reactive to proactive healthcare by potentially enabling round-the-clock, real-time, non-invasive monitoring of a person’s health and well-being, thereby empowering clinicians to personalize care with actionable data. “This partnership combines Medtronic’s exceptional strength in providing in-patient care with Rockley’s expertise in wearable, remote monitoring. I believe that this collaboration will bring to life our vision of giving people better insights into their health and well-being. We are excited about the potential for this partnership to herald the next generation of wearable devices and deliver a complete lifecycle of patient care.” Dr. Andrew Rickman, chairman and chief executive officer of Rockley About Rockley Photonics A global leader in photonics-based health monitoring and communications solutions, Rockley Photonics is developing a comprehensive range of photonic integrated circuits and associated modules, sensors, and full-stack solutions. From next-generation sensing platforms specifically designed for mobile health monitoring and machine vision to high-speed, high-volume solutions for data communications, Rockley is laying the foundation for a new generation of applications across multiple industries. Rockley believes that photonics will eventually become as pervasive as micro-electronics, and it has developed a platform with the power and flexibility needed to address both mass markets and a wide variety of vertical applications.

Read More

Spotlight

Imagine a nurse, let’s call her Jill, who faces multiple “scrub-ins” every day as part of her operating room (OR) role. She struggles with a rash on her hands and wrists that just won’t go away, causing both physical and emotional trauma. These recurring and often painful skin conditions – which range from mild irritations to more serious reactions – can persist, despite the care taken by nurses and hospitals. Add to that the toll in sick leaves and absenteeism, and the cost of this condition can be painful to both staff and administration. Despite the care and costs, hospitals have not solved the problem. But there is an answer!

Resources